AI-generated summary
The authors tested four LED red light wavelengths on two breast cancer-origin cell lines in vitro. They report that only 660 nm light reduced cell viability, by about 40% at 24 hours, and that treated cells showed signs of autophagy. The study was conducted on cell lines rather than people, and the authors suggest the approach may be developed as a cancer treatment in future.
- Who or what was studied
- Non-triple negative (MCF-7) and triple negative (MDA-MB-231) breast cancer-origin cell lines, in vitro
- Wavelengths
- 615, 630, 660, 730 nm
- Limits stated in the abstract
- The study was conducted only in vitro on cell lines, so its findings do not establish effects in humans.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 730 nm, 660 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Light-emitting diode, Red light therapy, Wavelength. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.